Cardiology Department, Assistance publique-Hôpitaux de Paris and université Pierre-et-Marie-Curie, Saint-Antoine University and Medical School, 75571 Paris cedex 12, France.
Arch Cardiovasc Dis. 2010 Jun-Jul;103(6-7):376-87. doi: 10.1016/j.acvd.2010.06.001. Epub 2010 Jul 22.
Limited French data are available for the different clinical types (paroxysmal, persistent and permanent) of atrial fibrillation and their comorbidities (AF).
To provide contemporary insights into the characteristics and management of outpatients with a history of or current AF in France.
EPHA is a national, observational, cross-sectional, multicentre descriptive study with retrospective data collection relating to the management, treatment and hospitalization of patients with AF.
One thousand three hundred and thirty-one patients (mean age: 74 +/- 11 years [55.7% > or =75 years]; 58.8% men) were included into the study between February 2009 and May 2009; their data were collected during the past 12 months. Of these, 38.2% had paroxysmal AF, 10.0% persistent AF and 51.8% permanent AF. Most patients had at least one cardiovascular risk factor (80.8%). Almost all patients (96.6%) had received an antiarrhythmic drug in the previous year, of which 59.6% received a rhythm control strategy (class I, class III) with or without rate control strategy (class II, class IV, digitalis) and 40.6% received a rate control strategy exclusively. Almost all (94.4%) patients were treated with an antithrombotic: 83.4% with a vitamin K antagonist and 21.9% with antiplatelet therapy. Almost one-fifth (18.4%) of patients had been hospitalized related to AF at least once in the previous year. Patients with paroxysmal and persistent AF were hospitalized more frequently (20.0% and 31.1%, respectively) than patients with permanent AF (14.8%).
About half of the patients had paroxysmal or persistent AF. Four-fifths of AF patients had at least one cardiovascular risk factor. The use of antiarrhythmic and antithrombotic treatments was very high. The rhythm control strategy was preferred in patients with paroxysmal or persistent AF.
有关心房颤动(AF)不同临床类型(阵发性、持续性和永久性)及其合并症的法国数据有限。
提供法国当前关于有或无 AF 病史的门诊患者特征和管理的最新信息。
EPHA 是一项全国性、观察性、横断面、多中心描述性研究,回顾性收集与 AF 患者的管理、治疗和住院情况相关的数据。
2009 年 2 月至 5 月期间,共纳入 1331 例(平均年龄:74 +/- 11 岁[55.7% ≥ 75 岁];58.8%为男性)患者,数据采集于过去 12 个月。其中,38.2%为阵发性 AF,10.0%为持续性 AF,51.8%为永久性 AF。大多数患者至少存在 1 项心血管危险因素(80.8%)。几乎所有患者(96.6%)在过去 1 年内均接受过抗心律失常药物治疗,其中 59.6%接受节律控制策略(I 类、III 类),联合或不联合心率控制策略(II 类、IV 类、地高辛),40.6%仅接受心率控制策略。几乎所有(94.4%)患者接受抗血栓治疗:83.4%接受维生素 K 拮抗剂,21.9%接受抗血小板治疗。近五分之一(18.4%)患者在过去 1 年内至少因 AF 住院治疗 1 次。阵发性和持续性 AF 患者的住院率(分别为 20.0%和 31.1%)高于永久性 AF 患者(14.8%)。
约一半的患者为阵发性或持续性 AF。五分之四的 AF 患者至少存在 1 项心血管危险因素。抗心律失常和抗血栓治疗的使用率非常高。阵发性或持续性 AF 患者中更倾向于使用节律控制策略。